Auricle vs Vinci
Side-by-side comparison of AI visibility scores, market position, and capabilities
Neurostimulation implant for hearing restoration beyond hearing aids; targeting 3.5M US patients in the gap between aids and cochlear implants with Fogarty Innovation backing.
About
Auricle is a medical device company developing a neurostimulation implant designed to restore hearing for patients with moderate-to-severe hearing loss who no longer receive adequate benefit from conventional hearing aids — addressing a population of approximately 3.5 million patients in the US who have exhausted hearing aid options but may not qualify for or desire cochlear implants. Founded in 2020 in Mountain View, California and a Y Combinator W21 graduate, Auricle raised $500,000 from YC, Digilife, Fogarty Innovation, North South Ventures, and StartX, achieving $1.4 million in revenue in 2024 with 9 employees.\n\nAuricle's device uses electrical stimulation of the auditory nerve or cochlea in a minimally invasive implant procedure, providing amplification and sound clarity beyond what hearing aids can achieve by directly stimulating the neural pathway rather than amplifying acoustic sound. The device targets the significant gap between hearing aids (non-surgical, limited for severe loss) and cochlear implants (extensive surgery, full inner ear destruction) — offering a middle-ground intervention for patients with moderate-to-severe loss who want more than hearing aids provide. The $1.2 billion addressable market represents the unmet need in this underserved gap.\n\nIn 2025, Auricle is in the pre-market regulatory and clinical validation phase, working toward FDA clearance for its neurostimulation approach. The hearing device market is dominated by Cochlear Limited, Advanced Bionics (Sonova), and MED-EL for implantable hearing devices, alongside Starkey, Phonak, Oticon, and ReSound for hearing aids. Fogarty Innovation's backing indicates strong clinical mentorship — Fogarty is the leading medical device incubator associated with Thomas Fogarty, a legendary medical device inventor. The 2025-2026 strategy focuses on completing clinical studies demonstrating efficacy and safety, building the regulatory submission, and establishing clinical partnerships with ENT and audiology centers.
Nanterre global concessions and construction (EPA: DG, CAC 40) at €71.6B 2024 revenue record and €4.9B net income; 72 airports/4,400km toll roads with Edinburgh Airport acquisition competing with ACS for global infrastructure concessions.
About
VINCI SA is a Nanterre, France-headquartered global concessions and construction group — listed on Euronext Paris (EPA: DG) as a CAC 40 component — reporting record €71.6 billion in revenue and €4.9 billion in net income for 2024, employing 285,000 people across 120+ countries in three business divisions: Vinci Concessions (€11.7 billion revenue, operating 4,400 km of toll roads and 72 airports including Gatwick and Edinburgh airports in 14 countries), Vinci Energies (€27.5 billion revenue, energy transition and digital infrastructure services), and Vinci Construction (€31.8 billion revenue, civil engineering, buildings, and hydraulic engineering). International markets represent 58% of total revenue. CEO Xavier Huillard has led VINCI since 2010; Pierre Anjolras serves as incoming COO. Key acquisitions include ANA Aeroportos de Portugal (€3.08B, 2012), Gatwick Airport 50.01% (2019), ACS Industrial Services division (€5.2B, 2021), and Edinburgh Airport 50.01% (2024). Founded 1899 as Société Générale d'Entreprises.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.